Benefit of monoclonal antibodies in early treatment of COVID-19 after lung transplantation: a retrospective analysis in two centres

Treatment with monoclonal antibodies was associated with improved survival in COVID-19 after lung transplantation (LTx). Age was a negative independent predictor of survival in this cohort of 133 COVID-19 cases after LTx. https://bit.ly/3kx5CBw

Detalles Bibliográficos
Autores principales: Gottlieb, Jens, Kolditz, Martin, Gade, Nils, Welte, Tobias, Kneidinger, Nikolaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301052/
https://www.ncbi.nlm.nih.gov/pubmed/35618274
http://dx.doi.org/10.1183/13993003.00124-2022
_version_ 1784751348590313472
author Gottlieb, Jens
Kolditz, Martin
Gade, Nils
Welte, Tobias
Kneidinger, Nikolaus
author_facet Gottlieb, Jens
Kolditz, Martin
Gade, Nils
Welte, Tobias
Kneidinger, Nikolaus
author_sort Gottlieb, Jens
collection PubMed
description Treatment with monoclonal antibodies was associated with improved survival in COVID-19 after lung transplantation (LTx). Age was a negative independent predictor of survival in this cohort of 133 COVID-19 cases after LTx. https://bit.ly/3kx5CBw
format Online
Article
Text
id pubmed-9301052
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-93010522022-07-22 Benefit of monoclonal antibodies in early treatment of COVID-19 after lung transplantation: a retrospective analysis in two centres Gottlieb, Jens Kolditz, Martin Gade, Nils Welte, Tobias Kneidinger, Nikolaus Eur Respir J Research Letters Treatment with monoclonal antibodies was associated with improved survival in COVID-19 after lung transplantation (LTx). Age was a negative independent predictor of survival in this cohort of 133 COVID-19 cases after LTx. https://bit.ly/3kx5CBw European Respiratory Society 2022-07-21 /pmc/articles/PMC9301052/ /pubmed/35618274 http://dx.doi.org/10.1183/13993003.00124-2022 Text en Copyright ©The authors 2022. https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Research Letters
Gottlieb, Jens
Kolditz, Martin
Gade, Nils
Welte, Tobias
Kneidinger, Nikolaus
Benefit of monoclonal antibodies in early treatment of COVID-19 after lung transplantation: a retrospective analysis in two centres
title Benefit of monoclonal antibodies in early treatment of COVID-19 after lung transplantation: a retrospective analysis in two centres
title_full Benefit of monoclonal antibodies in early treatment of COVID-19 after lung transplantation: a retrospective analysis in two centres
title_fullStr Benefit of monoclonal antibodies in early treatment of COVID-19 after lung transplantation: a retrospective analysis in two centres
title_full_unstemmed Benefit of monoclonal antibodies in early treatment of COVID-19 after lung transplantation: a retrospective analysis in two centres
title_short Benefit of monoclonal antibodies in early treatment of COVID-19 after lung transplantation: a retrospective analysis in two centres
title_sort benefit of monoclonal antibodies in early treatment of covid-19 after lung transplantation: a retrospective analysis in two centres
topic Research Letters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301052/
https://www.ncbi.nlm.nih.gov/pubmed/35618274
http://dx.doi.org/10.1183/13993003.00124-2022
work_keys_str_mv AT gottliebjens benefitofmonoclonalantibodiesinearlytreatmentofcovid19afterlungtransplantationaretrospectiveanalysisintwocentres
AT kolditzmartin benefitofmonoclonalantibodiesinearlytreatmentofcovid19afterlungtransplantationaretrospectiveanalysisintwocentres
AT gadenils benefitofmonoclonalantibodiesinearlytreatmentofcovid19afterlungtransplantationaretrospectiveanalysisintwocentres
AT weltetobias benefitofmonoclonalantibodiesinearlytreatmentofcovid19afterlungtransplantationaretrospectiveanalysisintwocentres
AT kneidingernikolaus benefitofmonoclonalantibodiesinearlytreatmentofcovid19afterlungtransplantationaretrospectiveanalysisintwocentres

Ejemplares similares